Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

Open access
Connor, Ashton A., Denroche, Robert E., Jang, Gun Ho, Timms, Lee, Kalimuthu, Sangeetha N., Selander, Iris, McPherson, Treasa, Wilson, Gavin W., Chan-Seng-Yue, Michelle A., Borozan, Ivan, Ferretti, Vincent, Grant, Robert C., Lungu, Ilinca M., Costello, Eithne, Greenhalf, William, Palmer, Daniel, Ghaneh, Paula, Neoptolemos, John P., Buchler, Markus, Petersen, Gloria, Thayer, Sarah, Hollingsworth, Michael A., Sherker, Alana, Durocher, Daniel, Dhani, Neesha, Hedley, David, Serra, Stefano, Pollett, Aaron, Roehrl, Michael H. A., Bavi, Prashant, Bartlett, John M. S., Cleary, Sean, Wilson, Julie M., Alexandrov, Ludmil B., Moore, Malcolm, Wouters, Bradly G., McPherson, John D., Notta, Faiyaz, Stein, Lincoln D., Gallinger, Steven·2017·JAMA Oncology

Abstract

IMPORTANCE: Outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. Advances in next-generation sequencing provide a route to therapeutic approaches, and integrating DNA and RNA analysis with clinicopathologic data may be a crucial step toward personalized treatment strategies for this disease. OBJECTIVE: To classify PDAC according to distinct mutational processes, and explore their clinical significance. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective cohort study of resected PDAC, using cases collected between 2008 and 2015 as part of the International Cancer Genome Consortium. The discovery cohort comprised 160 PDAC cases from 154 patients (148 primary; 12 metastases) that underwent tumor enrichment prior to whole-genome and RNA sequencing. The replication cohort comprised 95 primary PDAC cases that underwent whole-genome sequencing and expression microarray on bulk biospecimens. MAIN OUTCOMES AND MEASURES: Somatic mutations accumulate from sequence-specific processes creating signatures detectable by DNA sequencing. Using nonnegative matrix factorization, we measured the contribution of each signature to carcinogenesis, and used hierarchical clustering to subtype each cohort. We examined expression of antitumor immunity genes across subtypes to uncover biomarkers predictive of response to systemic therapies. RESULTS: The discovery cohort was 53% male (n = 79) and had a median age of 67 (interquartile range, 58-74) years. The replication cohort was 50% male (n = 48) and had a median age of 68 (interquartile range, 60-75) years. Five predominant mutational subtypes were identified that clustered PDAC into 4 major subtypes: age related, double-strand break repair, mismatch repair, and 1 with unknown etiology (signature 8). These were replicated and validated. Signatures were faithfully propagated from primaries to matched metastases, implying their stability during carcinogenesis. Twelve of 27 (45%) double-strand break repair cases lacked germline or somatic events in canonical homologous recombination genes-BRCA1, BRCA2, or PALB2. Double-strand break repair and mismatch repair subtypes were associated with increased expression of antitumor immunity, including activation of CD8-positive T lymphocytes (GZMA and PRF1) and overexpression of regulatory molecules (cytotoxic T-lymphocyte antigen 4, programmed cell death 1, and indolamine 2,3-dioxygenase 1), corresponding to higher frequency of somatic mutations and tumor-specific neoantigens. CONCLUSIONS AND RELEVANCE: Signature-based subtyping may guide personalized therapy of PDAC in the context of biomarker-driven prospective trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.3916

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 289

Metadata

Authors
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., McPherson, T., Wilson, G. W., Chan-Seng-Yue, M. A., Borozan, I., Ferretti, V., Grant, R. C., Lungu, I. M., Costello, E., Greenhalf, W., Palmer, D., Ghaneh, P., Neoptolemos, J. P., Buchler, M., Petersen, G., Thayer, S., Hollingsworth, M. A., Sherker, A., Durocher, D., Dhani, N., Hedley, D., Serra, S., Pollett, A., Roehrl, M. H. A., Bavi, P., Bartlett, J. M. S., Cleary, S., Wilson, J. M., Alexandrov, L. B., Moore, M., Wouters, B. G., McPherson, J. D., Notta, F., Stein, L. D., & Gallinger, S.
Venue
JAMA Oncology
Published
2017-06-01
Volume
3
Issue
6
Pages
774
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2536154437
Cited by
289
References
67
FWCI
11.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1001/jamaoncol.2016.3916
The paper
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L., Kalimuthu, S. N., Selander, I., McPherson, T., Wilson, G. W., Chan-Seng-Yue, M. A., Borozan, I., Ferretti, V., Grant, R. C., Lungu, I. M., Costello, E., Greenhalf, W., Palmer, D., Ghaneh, P., Neoptolemos, J. P., Buchler, M., . . . Gallinger, S. (2017). Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2016.3916

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.